Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-? agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-? agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.
Revenue (Most Recent Fiscal Year) | -- |
Net Income (Most Recent Fiscal Year) | $-202.24M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | -- |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 7.23 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -- |
Net Margin (Trailing 12 Months) | -- |
Return on Equity (Trailing 12 Months) | -64.30% |
Return on Assets (Trailing 12 Months) | -56.71% |
Current Ratio (Most Recent Fiscal Quarter) | 6.13 |
Quick Ratio (Most Recent Fiscal Quarter) | 6.13 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $15.52 |
Earnings per Share (Most Recent Fiscal Quarter) | $-3.82 |
Earnings per Share (Most Recent Fiscal Year) | $-13.09 |
Diluted Earnings per Share (Trailing 12 Months) | $-13.09 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Biotechnology |
Common Shares Outstanding | 16.02M |
Free Float | 9.31M |
Market Capitalization | $1.80B |
Average Volume (Last 20 Days) | 0.18M |
Beta (Past 60 Months) | 0.99 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 41.89% |
Percentage Held By Institutions (Latest 13F Reports) | 78.22% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |